Mario Palma
@mariopalma.bsky.social
Postdoctoral Fellow in the Ubellacker Lab at Harvard T.H. Chan School of Public Health. Focused on studying ferroptosis, cancer signaling, and lymph metastasis.
Pinned
Lymph node environment drives FSP1 targetability in metastasizing melanoma - Nature
Targeting FSP1 in lymph nodes has considerable potential for blocking melanoma progression.
www.nature.com
Excited to share my postdoctoral work, out today in Nature! www.nature.com/articles/s41...
We discovered that melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits melanoma progression.
We discovered that melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits melanoma progression.
Reposted by Mario Palma
new out in Nature, targeting FSP1 to trigger ferroptosis
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Targeting FSP1 triggers ferroptosis in lung cancer - Nature
The ferroptosis suppressor protein FSP1 has a critical role in ferroptosis protection of tumours across multiple in vivo models and is linked to worse prognosis in human lung adenocarcinoma, suggestin...
www.nature.com
November 6, 2025 at 7:39 AM
new out in Nature, targeting FSP1 to trigger ferroptosis
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Mario Palma
Melanoma cells that spread to lymph nodes depend on FSP1 to survive, revealing a new metabolic vulnerability. New study in Nature by @mariopalma.bsky.social @ubellackerlab.bsky.social and colleagues shows that blocking FSP1 triggers ferroptosis and suppresses tumor growth in lymph node metastases.
Lymph node environment drives FSP1 targetability in metastasizing melanoma - Nature
Targeting FSP1 in lymph nodes has considerable potential for blocking melanoma progression.
www.nature.com
November 5, 2025 at 5:28 PM
Melanoma cells that spread to lymph nodes depend on FSP1 to survive, revealing a new metabolic vulnerability. New study in Nature by @mariopalma.bsky.social @ubellackerlab.bsky.social and colleagues shows that blocking FSP1 triggers ferroptosis and suppresses tumor growth in lymph node metastases.
Excited to share my postdoctoral work, out today in Nature! www.nature.com/articles/s41...
We discovered that melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits melanoma progression.
We discovered that melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits melanoma progression.
Lymph node environment drives FSP1 targetability in metastasizing melanoma - Nature
Targeting FSP1 in lymph nodes has considerable potential for blocking melanoma progression.
www.nature.com
November 5, 2025 at 4:35 PM
Excited to share my postdoctoral work, out today in Nature! www.nature.com/articles/s41...
We discovered that melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits melanoma progression.
We discovered that melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits melanoma progression.
Reposted by Mario Palma
Join me in Boston October 6th for a 1-day conference on #mappingbiology to transform #cancertherapeutics. Register by September 25th to benefit from the complimentary (free) admission! Topics, speakers, and talk opportunities here: abcam.me/mappingbiolo...
@abcamofficial.bsky.social
@abcamofficial.bsky.social
August 5, 2025 at 6:59 PM
Join me in Boston October 6th for a 1-day conference on #mappingbiology to transform #cancertherapeutics. Register by September 25th to benefit from the complimentary (free) admission! Topics, speakers, and talk opportunities here: abcam.me/mappingbiolo...
@abcamofficial.bsky.social
@abcamofficial.bsky.social
Reposted by Mario Palma
Our team (hsph.harvard.edu/research/ube...) is excited to have contributed to the intranodal in vivo testing of the remarkable new compound, Fentomycin-1. Congrats to team Rodriguez et al. for the implications of this work in targeting ferroptosis in cancer. Check it out here!
new out in Nature, very cool story www.nature.com/articles/s41...
Activation of lysosomal iron triggers ferroptosis in cancer - Nature
Some cancer cells exhibit high loads of reactive iron in lysosomes, and this feature is exploited by using fentomycin-1, a newly developed small molecule, to induce ferroptosis.
www.nature.com
May 7, 2025 at 3:57 PM
Our team (hsph.harvard.edu/research/ube...) is excited to have contributed to the intranodal in vivo testing of the remarkable new compound, Fentomycin-1. Congrats to team Rodriguez et al. for the implications of this work in targeting ferroptosis in cancer. Check it out here!
Reposted by Mario Palma
For more than 100 years, Harvard Chan School has worked to build a world where everyone can thrive.
Our discoveries and solutions have improved life for millions of people around the globe. And we’re expanding that impact every day.
Our discoveries and solutions have improved life for millions of people around the globe. And we’re expanding that impact every day.
April 23, 2025 at 7:20 PM
For more than 100 years, Harvard Chan School has worked to build a world where everyone can thrive.
Our discoveries and solutions have improved life for millions of people around the globe. And we’re expanding that impact every day.
Our discoveries and solutions have improved life for millions of people around the globe. And we’re expanding that impact every day.
Reposted by Mario Palma
A reminder that for next month’s BCDI in place of our regular discussion, we encourage you to attend the Cutter Distinguished Lecture @met-hsph.bsky.social by the great Scott Dixon!
See you there: Monday May 12, 2025, Kresge Building at HSPH, G1 auditorium, 12:00-1:00pm
See you there: Monday May 12, 2025, Kresge Building at HSPH, G1 auditorium, 12:00-1:00pm
April 18, 2025 at 3:13 PM
A reminder that for next month’s BCDI in place of our regular discussion, we encourage you to attend the Cutter Distinguished Lecture @met-hsph.bsky.social by the great Scott Dixon!
See you there: Monday May 12, 2025, Kresge Building at HSPH, G1 auditorium, 12:00-1:00pm
See you there: Monday May 12, 2025, Kresge Building at HSPH, G1 auditorium, 12:00-1:00pm
Reposted by Mario Palma
Short on time wrangling research hurdles or just life in general? @mariopalma.bsky.social and @mariesabatier.bsky.social have you covered with this focused spotlight on Ueda et al.’s work in Nature Cell Biology on oxidative niches and cancer cell dissemination. Spotlight article here: rb.gy/zi8wj9
April 15, 2025 at 11:24 PM
Short on time wrangling research hurdles or just life in general? @mariopalma.bsky.social and @mariesabatier.bsky.social have you covered with this focused spotlight on Ueda et al.’s work in Nature Cell Biology on oxidative niches and cancer cell dissemination. Spotlight article here: rb.gy/zi8wj9
Reposted by Mario Palma
🌟 Excited to share our latest spotlight! 🌟 Co-wrote with @mariopalma.bsky.social and Jessalyn @ubellackerlab.bsky.social, highlighting Ueda et al.'s study on oxidative niches driving immune evasion in tumors.
Check out our spotlight article here: rb.gy/zi8wj9
Ueda et al., 2025: rb.gy/674im7
Check out our spotlight article here: rb.gy/zi8wj9
Ueda et al., 2025: rb.gy/674im7
April 15, 2025 at 4:36 PM
🌟 Excited to share our latest spotlight! 🌟 Co-wrote with @mariopalma.bsky.social and Jessalyn @ubellackerlab.bsky.social, highlighting Ueda et al.'s study on oxidative niches driving immune evasion in tumors.
Check out our spotlight article here: rb.gy/zi8wj9
Ueda et al., 2025: rb.gy/674im7
Check out our spotlight article here: rb.gy/zi8wj9
Ueda et al., 2025: rb.gy/674im7
Reposted by Mario Palma
Great news for AKT inhibitors! Capivasertib in combo with abiraterone and ADT improves progression free survival in PTEN deficient prostate cancer! Anticipating approval for this combo, coming off the approval of capi in ER+be breast cancer. Good work AZ!
www.onclive.com/view/capivas...
www.onclive.com/view/capivas...
Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC
Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.
www.onclive.com
November 26, 2024 at 5:45 PM
Great news for AKT inhibitors! Capivasertib in combo with abiraterone and ADT improves progression free survival in PTEN deficient prostate cancer! Anticipating approval for this combo, coming off the approval of capi in ER+be breast cancer. Good work AZ!
www.onclive.com/view/capivas...
www.onclive.com/view/capivas...